210 related articles for article (PubMed ID: 27306814)
1. [An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Sakiyama K; Yoshida T; Goto Y; Kimura M
Gan To Kagaku Ryoho; 2016 Jun; 43(6):753-5. PubMed ID: 27306814
[TBL] [Abstract][Full Text] [Related]
2. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
[TBL] [Abstract][Full Text] [Related]
3. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
[TBL] [Abstract][Full Text] [Related]
4. [Everolimus plus Exemestane in Postmenopausal Metastatic Breast Cancer Patients].
Yamamoto D; Tsubota Y; Sueoka N; Yamamoto C; Kon M
Gan To Kagaku Ryoho; 2015 Oct; 42(10):1319-21. PubMed ID: 26489585
[TBL] [Abstract][Full Text] [Related]
5. [Ethinylestradiol Following Everolimus plus Exemestane Was Effective in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer - A Case Report].
Matsuoka A; Hirano A; Hattori A; Ogura K; Inoue H; Yukawa H; Sakaguchi S; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1219-1222. PubMed ID: 27760942
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients].
Maeda N; Yamamoto S; Sato Y; Sakamoto K; Suzuki N; Takeda S; Nagashima Y; Kubo H; Nagano H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1260-1262. PubMed ID: 29394600
[TBL] [Abstract][Full Text] [Related]
7. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Metastatic Breast Cancer That Recovered from Diffuse Alveolar Damage Associated with Everolims].
Kinoshita H; Teraoka H; Hasegawa T; Nakamoto K; Kashiwagi S; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2370-2372. PubMed ID: 33468964
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Ciruelos E; Jerusalem G; Martin M; Tjan-Heijnen VCG; Neven P; Gavila J; Montemurro F; Generali D; Lang I; Martínez-Serrano MJ; Perelló MF; Conte P
Clin Transl Oncol; 2020 Oct; 22(10):1857-1866. PubMed ID: 32170637
[TBL] [Abstract][Full Text] [Related]
10. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Ciruelos E; Vidal M; Martínez de Dueñas E; Martínez-Jáñez N; Fernández Y; García-Sáenz JA; Murillo L; Carabantes F; Beliera A; Fonseca R; Gavilá J
Clin Transl Oncol; 2018 Jun; 20(6):753-760. PubMed ID: 29116433
[TBL] [Abstract][Full Text] [Related]
11. Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report.
Ballatore Z; Pistelli M; Battelli N; Pagliacci A; De Lisa M; Berardi R; Cascinu S
BMC Res Notes; 2016 Nov; 9(1):497. PubMed ID: 27894335
[TBL] [Abstract][Full Text] [Related]
12. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Moscetti L; Vici P; Gamucci T; Natoli C; Cortesi E; Marchetti P; Santini D; Giuliani R; Sperduti I; Mauri M; Pizzuti L; Mancini ML; Fabbri MA; Magri V; Iezzi L; Sini V; D'Onofrio L; Mentuccia L; Vaccaro A; Ramponi S; Roma CL; Ruggeri EM
Breast; 2016 Oct; 29():96-101. PubMed ID: 27476084
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Recurrent Breast Cancer with Bone Metastasis Successfully Treated with Everolimus and Exemestane Therapy].
Kubo H; Kimura Y; Kawaoka T; Miyahara M; Shimizu R; Nagashima Y; Yamamoto S; Nagano H
Gan To Kagaku Ryoho; 2017 Feb; 44(2):157-160. PubMed ID: 28223674
[TBL] [Abstract][Full Text] [Related]
14. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M; Fabi A; Moscetti L; Cazzaniga ME; Petrucelli L; Forcignanò R; Lupo LI; De Matteis E; Chiuri VE; Cairo G; Febbraro A; Giordano G; Giampaglia M; Bilancia D; La Verde N; Maiello E; Morritti M; Giotta F; Lorusso V; Latorre A; Scavelli C; Romito S; Cusmai A; Palmiotti G; Surico G
Breast Cancer Res Treat; 2017 Jun; 163(3):587-594. PubMed ID: 28353061
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
16. [A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Suzuki M
Gan To Kagaku Ryoho; 2007 Jan; 34(1):69-72. PubMed ID: 17220673
[TBL] [Abstract][Full Text] [Related]
17. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
18. [Subclavian Artery Hemorrhage Related to Everolimus in a Patient with Recurrent Breast Cancer--A Case Report].
Kakimoto M; Nakata T; Imaizumi K; Hirano T; Murata T; Okuno K; Hoshino M; Matsuyama T; Goto H; Koshiishi H; Yoshimura T; Osanai T; Suzuki K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1806-8. PubMed ID: 26805179
[TBL] [Abstract][Full Text] [Related]
19. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
Gilabert M; Launay S; Gonçalves A
Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
[TBL] [Abstract][Full Text] [Related]
20. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone M; Yang H; Faust E; Kageleiry A; Signorovitch JE; Zhang J; Gao H
J Med Econ; 2014 Dec; 17(12):837-45. PubMed ID: 25164472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
